.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Novartis
US Department of Justice
UBS
AstraZeneca
Johnson and Johnson
Cipla
Farmers Insurance
QuintilesIMS
Healthtrust

Generated: November 24, 2017

Sudan (ARIPO) Drug Patents

Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Liberia, Rwanda, São Tomé and Príncipe, Sierra Leone, Somalia, Sudan, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe

These international patent data are derived from patent families, based on US drug-patent linkages.
They should not be regarded as comprehensive records of ex-US drug-patent associations.

Document Number Estimated Expiration Equivalent US Patent US Expiry Date Generic Name US Applicant US Tradename
3903► Subscribe9296782Jul 17, 2034
sofosbuvir; velpatasvir; voxilaprevir
Gilead Sciences Inc
VOSEVI
201407875► Subscribe8865730Mar 5, 2033
idelalisib
Gilead Sciences Inc
ZYDELIG
201407699► Subscribe8889159Mar 26, 2029
ledipasvir; sofosbuvir
Gilead Sciences Inc
HARVONI
201407699► Subscribe8889159Mar 26, 2029
sofosbuvir; velpatasvir
Gilead Sciences Inc
EPCLUSA
201407699► Subscribe8889159Mar 26, 2029
sofosbuvir
Gilead Sciences Inc
SOVALDI
201407699► Subscribe8889159Mar 26, 2029
sofosbuvir; velpatasvir; voxilaprevir
Gilead Sciences Inc
VOSEVI
201407575► Subscribe8889159Mar 26, 2029
ledipasvir; sofosbuvir
Gilead Sciences Inc
HARVONI
201407575► Subscribe8889159Mar 26, 2029
sofosbuvir; velpatasvir
Gilead Sciences Inc
EPCLUSA
201407575► Subscribe8889159Mar 26, 2029
sofosbuvir
Gilead Sciences Inc
SOVALDI
201407575► Subscribe8889159Mar 26, 2029
sofosbuvir; velpatasvir; voxilaprevir
Gilead Sciences Inc
VOSEVI
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
QuintilesIMS
Merck
Harvard Business School
Julphar
UBS
Chinese Patent Office
Cipla
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot